AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback